Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents (HGG-CilMetro)

This study is currently recruiting participants.
Verified January 2012 by Martin-Luther-Universität Halle-Wittenberg
Sponsor:
Collaborator:
Merck KGaA
Information provided by (Responsible Party):
Christof Kramm, Martin-Luther-Universität Halle-Wittenberg
ClinicalTrials.gov Identifier:
NCT01517776
First received: January 11, 2012
Last updated: January 20, 2012
Last verified: January 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2015
  Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)